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Fig 2. Ultrasound (U/S) velocity ratio progression over time.
Table. Relationship of duplex and computed tomography (CT) scan
ﬁndings and graft failure
Graft status
P valueFailed, No. (%) Patent, No. (%)
U/S velocity ratio
<2.0 3 (0.5) 622 (99.5) <.001a
2.0-3.5 3 (12) 22 (88)
>3.5 4 (67) 2 (33)
CT stenosis
0-49% 0 (0) 578 (100) <.001a
50-59% 2 (5) 35 (95)
60-69% 5 (22) 18 (78)
70-79% 2 (14) 12 (86)
>80% 1 (25) 3 (75)
U/S, Ultrasound.
aFisher’s exact test.
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Volume 60, Number 6 Abstracts 1717Conclusions: Our analysis demonstrates that signiﬁcantly elevated
U/S velocity ratios >3.5 are strongly correlated with graft failure and also
that low and even moderate CT stenosis correlate with graft success. We
show that a moderately elevated U/S velocity ratio in the 2 to 3.5 range
is largely clinically benign, with few of these grafts ultimately failing and
that velocity ratios for this group tend to improve with time. This is a
step toward deﬁning the relationship between imaging and outcome for
vein grafts, an understanding of which will likely contribute to the establish-
ment of the optimal strategy for graft monitoring.
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Introduction: Limited single-center experiences with the treatment
of infected endovascular endografts (I-EVAR) have been reported. We per-
formed a multicenter review of the surgical care of these patients to eluci-
date short-term and long-term outcomes.
Methods: A retrospective analysis of all EVAR explants from 2000 to
2014 at four institutionswas performed. Patients with I-EVAR undergoing sur-
gical treatmentwere reviewed.Datawereobtaineddetailingpreoperative patient
demographics, postoperativemorbidity andmortality, and long-term follow-up.
Results: Thirty-six patients, 30 male (83%) and six female (17%), with a
median age of 69 years (range, 54-80 years), were treated with endovascular
graft excision and revascularization for I-EVAR. Average time from initial
EVAR to explantation was 589 days (range, 43-2466 days). Preoperativecomorbidities include hypertension, 32 (89%); tobacco use, 31 (86%); coro-
nary artery disease, 26 (72%); hyperlipidemia, 25 (69%); peripheral arterial dis-
ease, 13 (36%); cerebrovascular disease, 10 (28%); diabetes, 10 (28%); chronic
obstructive pulmonary disease, 9 (25%); and chronic kidney disease, 9 (25%).
The most common presenting symptoms were leukocytosis in 23 (63%), pain
in 21 (58%), and fever in 20 (56%), which were present an average of 22 days
prior to explantation. Eight different types of endograft were removed. Three
patients (8%) underwent emergency explantation. Thirty-two patients under-
went total graft excision (89%), and four patients underwent partial excision
(11%). Methods of reconstruction included in situ reconstruction in 25
(69%) and extra-anatomic reconstruction in 11 (31%). Conduits used in
reconstruction consisted of Dacron, with or without rifampin treatment, poly-
tetraﬂuoroethylene, cryopreserved allograft, and superﬁcial femoral vein.
Forty-nine organisms grew from operative cultures. Gram-positive organisms
were the most common isolate found in 32 (88%), including Staphylococcus in
12 (33%), and Streptococcus in six (17%). Anaerobic organisms were cultured
in 11 patients (31%), gram-negative organisms in 8 (22%), and fungus in 5
(14%). Amajority of patients (21 [58%]) were treated with long-term suppres-
sive antibiotic therapy. Early complications included acute renal failure in 12
(33%), respiratory failure requiring tracheostomy in 3 (8%), bleeding in 2
(6%), and sepsis in 2 (6%). Six patients required reexploration due to hema-
toma, infected hematoma, lymphatic leak, small-bowel perforation, open
abdomen at initial operation, and anastomotic bleeding. Perioperative mortal-
ity was 8% (3 of 36) and overall mortality was 25% (9 of 36) at a mean follow-
up of 402 days (range, 0-2472 days). Type of reconstruction (in situ vs extra-
anatomic) or conduit type did not affect perioperative or overall mortality.
Conclusions: I-EVAR is a rare but potentially devastating clinical
problem. Although perioperative mortality is acceptable, overall mortality
is high. The most common postoperative complication was acute renal fail-
ure; therefore, aortic cross-clamp time should be minimized. Although this
is the largest series of I-EVAR, further studies will be necessary to under-
stand risk factors and preventive measures.
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Introduction: The AORFIX endograft (Lombard Medical) is a highly
conformablemodular nitinol/polyester device designed for infrarenal or trans-
renal ﬁxation. PYTHAGORAS is the ﬁrst clinical trial to evaluate outcomes for
EVAR using AORFIX in highly angulated infrarenal aortic necks ($60).
Methods: PYTHAGORAS is a prospective nonrandomized clinical
trial that enrolled and treated 151 patients with neck angles $60 (high-an-
gle) and 67 patients with neck angles <60 (low-angle) in the EVAR group.
The primary control group was patients concurrently undergoing open repair
(n ¼ 76), and a meta-analysis of 323 patients from U.S. EVAR clinical trials
(Society for Vascular Surgery Lifeline) served as the secondary control. We
compared the high- and low-angle EVAR groups with the open group in
PYTHAGORAS in terms of mortality (30-day and 1-year) and freedom
from major adverse events (MAEs) deﬁned by the Society for Vascular Sur-
gery (myocardial infarction, cerebrovascular accident, renal failure, respira-
tory failure, paralysis/paraparesis, bowel ischemia, death, and bleeding)
using the Fisher exact test (Table I). Graft migration and type I and III endo-
leak were compared between high-angle and low-angle groups (Table II).
Results: Patient demographics and comorbidities were similar be-
tween the EVAR and open group with the exception of age (EVAR 76 6
8 vs open 70 6 7 years; P < .05), congestive heart failure (EVAR 13% vs
open 7% P ¼ .015), neck angle (EVAR all 71 6 23 and high angle 83
6 15 vs open 48 6 23; P < .05), and female gender (EVAR high angle
35% vs open 17%; P < .0001). Sac diameter and other anatomic variables
were similar. Operative data favored the EVAR group for procedure dura-
tion, blood loss, and hospital length of stay (all P < .05). There was no
statistically signiﬁcant difference between freedom from MAEs, 30-day,
and 1-year mortality between of low-angle or high-angle EVAR groups
compared with the PYTHAGOAS open control group (Table I). Also, there
was no difference between low-angle and high-angle patients in regards to
sac shrinkage, type I/III endoleak, and endograft migration (Table II).
Conclusions: PYTHAGORAS is the ﬁrst U.S. clinical trial designed
to evaluate the performance of EVAR in a population of patients with
neck angles $60. Despite signiﬁcant predictors of worse short-term and
long-term outcomes (female gender, congestive heart failure, neck angle),
MAEs and other pertinent outcomes were better or similar to open repair
